Is PRECISION BIOSCIENCES INC (DTIL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 27.1% / 30% | 77.8% / 30% | 1.5% / 30% | 9.84% / 5% | ✗ NOT HALAL |
| DJIM | 27.1% / 33% | 77.8% / 33% | 1.5% / 33% | 9.84% / 5% | ✗ NOT HALAL |
| MSCI | 22.0% / 33% | 63.3% / 33% | 1.2% / 33% | 9.84% / 5% | ✗ NOT HALAL |
| S&P | 27.1% / 33% | 77.8% / 33% | 1.5% / 33% | 9.84% / 5% | ✗ NOT HALAL |
| FTSE | 22.0% / 33% | 63.3% / 33% | 1.2% / 50% | 9.84% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | 36.6% | |
| Net Margin | -133.4% | |
| Return on Equity (ROE) | -62.7% | |
| Return on Assets (ROA) | -22.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$66M |
| Free Cash Flow | -$67M |
| Total Debt | $29M |
| Debt-to-Equity | 31.2 |
| Current Ratio | 13.3 |
| Total Assets | $154M |
Price & Trading
| Last Close | $6.54 |
| 50-Day MA | $4.67 |
| 200-Day MA | $5.00 |
| Avg Volume | 270K |
| Beta | 1.3 |
|
52-Week Range
$3.53
| |
About PRECISION BIOSCIENCES INC (DTIL)
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PRECISION BIOSCIENCES INC (DTIL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PRECISION BIOSCIENCES INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PRECISION BIOSCIENCES INC's debt ratio?
PRECISION BIOSCIENCES INC's debt ratio is 27.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.0%.
What are PRECISION BIOSCIENCES INC's key financial metrics?
PRECISION BIOSCIENCES INC has a market capitalization of $149M, and revenue of $34M. The company maintains a gross margin of 100.0% and a net margin of -133.4%. Return on equity stands at -62.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.